IP Library › Granted Patent US 12,296,008
Granted Patent B2
US 12,296,008 · App. 18/823,573 · Granted May 13, 2025

Pharmaceutical products and stable liquid compositions of IL-17 antibodies

Inventors: Susanne Joerg (Binningen, CH); Kathrin Serno-Schersch (Basel, CH)
Assignee: NOVARTIS AG
A61K39/39591C07K16/244C07K2317/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,296,008
App. No.
18/823,573
Granted
May 13, 2025
Kind
B2
Abstract

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

Claims (114)

1. A stable liquid pharmaceutical composition comprising:

(a) about 25 mg/mL to about 175 mg/mL secukinumab;

(b) at least 2.5 mM methionine;

(c) a buffer;

(d) a non-ionic stabilizer; and

(e) a surfactant;

wherein the composition has a pH of about 5.2 to about 6.2.

2. The composition of claim 1 , wherein the secukinumab is at a concentration of about 75 mg/mL to about 150 mg/mL.

3. The composition of claim 1 , wherein:

(a) the buffer is gluconate, histidine, citrate, phosphate, succinate, acetate, Tris, glycine, arginine, or a combination thereof;

(b) the non-ionic stabilizer is mannitol, trehalose, raffinose, maltose, sorbitol, or a combination thereof; or

(c) the surfactant is a polysorbate, a poloxamer, or a combination thereof.

4. The composition of claim 1 , wherein:

(a) the buffer is gluconate, histidine, citrate, phosphate, succinate, acetate, Tris, glycine, arginine, or a combination thereof;

(b) the non-ionic stabilizer is mannitol, trehalose, raffinose, maltose, sorbitol, or a combination thereof; and

(c) the surfactant is a polysorbate, a poloxamer, or a combination thereof.

5. The composition of claim 4 , wherein:

(a) the buffer is at a concentration of 10 mM to 30 mM;

(b) the non-ionic stabilizer is at a concentration of about 175 mM to about 350 mM; and

(c) the surfactant is at a concentration of 0.01% (w/v) to 0.04% (w/v).

6. The composition of claim 5 , wherein:

(a) the buffer comprises citrate;

(b) the non-ionic stabilizer is sorbitol; and

(c) the surfactant is polysorbate.

7. The composition of claim 1 , wherein upon storage at 2-8° C. for about 24 months:

(a) no more than 10% of secukinumab monomer is degraded as measured by size exclusion chromatography (SEC);

(b) no more than 10% of secukinumab main variant is degraded as measured by cation exchange chromatography (CEX); or

(c) no more than 10% of secukinumab main variant is degraded as measured by reverse phase-high performance liquid chromatography (RP-HPLC).

8. The composition of claim 1 , wherein upon storage at 2-8° C. for about 24 months:

(a) no more than 10% of secukinumab monomer is degraded as measured by size exclusion chromatography (SEC);

(b) no more than 10% of secukinumab main variant is degraded as measured by cation exchange chromatography (CEX); and

(c) no more than 10% of secukinumab main variant is degraded as measured by reverse phase-high performance liquid chromatography (RP-HPLC).

9. The composition of claim 1 , wherein upon storage at 25° C. for about 6 months:

(a) no more than 10% of secukinumab monomer is degraded as measured by size exclusion chromatography (SEC);

(b) no more than 10% of secukinumab main variant is degraded as measured by cation exchange chromatography (CEX); or

(c) no more than 10% of secukinumab main variant is degraded as measured by reverse phase-high performance liquid chromatography (RP-HPLC).

10. The composition of claim 1 , wherein upon storage at 25° C. for about 6 months:

(a) no more than 10% of secukinumab monomer is degraded as measured by size exclusion chromatography (SEC);

(b) no more than 10% of secukinumab main variant is degraded as measured by cation exchange chromatography (CEX); and

(c) no more than 10% of secukinumab main variant is degraded as measured by reverse phase-high performance liquid chromatography (RP-HPLC).

11. The composition of claim 7 , wherein the relative biological activity of secukinumab in the composition is at least 80% of a reference standard as measured by the inhibition of interleukin-6 (IL-6) release from human chondrocytes upon storage at 2-8° C. for about 24 months.

12. The composition of claim 8 , wherein the relative biological activity of secukinumab in the composition is at least 80% of a reference standard as measured by the inhibition of interleukin-6 (IL-6) release from human chondrocytes upon storage at 2-8° C. for about 24 months.

13. A liquid pharmaceutical composition comprising:

(a) about 25 mg/mL to about 175 mg/mL secukinumab;

(b) at least 2.5 mM methionine;

(c) a buffer;

(d) a non-ionic stabilizer; and

(e) a surfactant;

wherein the composition has a pH of 5.2 to 6.2; and

wherein no more than 10% of secukinumab monomer is degraded as measured by SEC upon storage at 2-8° C. for about 24 months.

14. The composition of claim 13 , wherein secukinumab is at a concentration of about 75 mg/mL to about 150 mg/mL.

15. The composition of claim 13 , wherein:

(a) the buffer is gluconate, histidine, citrate, phosphate, succinate, acetate, Tris, glycine, arginine, or a combination thereof;

(b) the non-ionic stabilizer is mannitol, trehalose, raffinose, maltose, sorbitol, or a combination thereof; and

(c) the surfactant is a polysorbate, a poloxamer, or a combination thereof.

16. The composition of claim 15 , wherein:

(a) the buffer is at a concentration of 10 mM to 30 mM;

(b) the non-ionic stabilizer is at a concentration of about 175 mM to about 350 mM; and

(c) the surfactant is at a concentration of 0.01% (w/v) to 0.04% (w/v).

17. The composition of claim 13 , wherein the relative biological activity of secukinumab in the composition is at least 80% of a reference standard as measured by the inhibition of interleukin-6 (IL-6) release from human chondrocytes upon storage at 2-8° C. for about 24 months.

18. A liquid pharmaceutical composition comprising:

(a) about 25 mg/mL to about 175 mg/mL secukinumab;

(b) at least 2.5 mM methionine;

(c) a buffer;

(d) a non-ionic stabilizer; and

(e) a surfactant;

wherein the composition has a pH of 5.2 to 6.2; and

wherein no more than 10% of secukinumab main variant is degraded as measured by CEX upon storage at 2-8° C. for about 24 months.

19. The composition of claim 18 , wherein secukinumab is at a concentration of about 75 mg/mL to about 150 mg/mL.

20. The composition of claim 18 , wherein:

(a) the buffer is gluconate, histidine, citrate, phosphate, succinate, acetate, Tris, glycine, arginine, or a combination thereof;

(b) the non-ionic stabilizer is mannitol, trehalose, raffinose, maltose, sorbitol, or a combination thereof; and

(c) the surfactant is a polysorbate, a poloxamer, or a combination thereof.

21. The composition of claim 20 , wherein:

(a) the buffer is at a concentration of 10 mM to 30 mM;

(b) the non-ionic stabilizer is at a concentration of about 175 mM to about 350 mM; and

(c) the surfactant is at a concentration of 0.01% (w/v) to 0.04% (w/v).

22. The composition of claim 18 , wherein the relative biological activity of secukinumab in the composition is at least 80% of a reference standard as measured by the inhibition of interleukin-6 (IL-6) release from human chondrocytes upon storage at 2-8° C. for about 24 months.

23. A liquid pharmaceutical composition comprising:

(a) about 25 mg/mL to about 175 mg/mL secukinumab;

(b) at least 2.5 mM methionine;

(c) a buffer;

(d) a non-ionic stabilizer; and

(e) a surfactant;

wherein the composition has a pH of 5.2 to 6.2; and

wherein no more than 10% of secukinumab main variant is degraded as measured by RP-HPLC upon storage at 2-8° C. for about 24 months.

24. The composition of claim 23 , wherein secukinumab is at a concentration of about 75 mg/mL to about 150 mg/mL.

25. The composition of claim 23 , wherein:

(a) the buffer is gluconate, histidine, citrate, phosphate, succinate, acetate, Tris, glycine, arginine, or a combination thereof;

(b) the non-ionic stabilizer is mannitol, trehalose, raffinose, maltose, sorbitol, or a combination thereof; and

(c) the surfactant is a polysorbate, a poloxamer, or a combination thereof.

26. The composition of claim 25 , wherein:

(a) the buffer is at a concentration of 10 mM to 30 mM;

(b) the non-ionic stabilizer is at a concentration of about 175 mM to about 350 mM; and

(c) the surfactant is at a concentration of 0.01% (w/v) to 0.04% (w/v).

27. The composition of claim 23 , wherein the relative biological activity of secukinumab in the composition is at least 80% of a reference standard as measured by the inhibition of interleukin-6 (IL-6) release from human chondrocytes upon storage at 2-8° C. for about 24 months.

28. The liquid composition of claim 23 , wherein no more than 10% of secukinumab monomer is degraded as measured by size exclusion chromatography (SEC) upon storage at 25° C. for about 6 months.

29. The composition of claim 28 , wherein:

(a) the buffer is gluconate, histidine, citrate, phosphate, succinate, acetate, Tris, glycine, arginine, or a combination thereof;

(b) the non-ionic stabilizer is mannitol, trehalose, raffinose, maltose, sorbitol, or a combination thereof; and

(c) the surfactant is a polysorbate, a poloxamer, or a combination thereof.

30. The composition of claim 29 , wherein:

(a) secukinumab is at a concentration of about 75 mg/mL to about 150 mg/mL;

(b) the buffer is at a concentration of 10 mM to 30 mM;

(c) the non-ionic stabilizer is at a concentration of about 175 mM to about 350 mM; and

(d) the surfactant is at a concentration of 0.01% (w/v) to 0.04% (w/v).

31. The composition of claim 2 , wherein the secukinumab is at a concentration of about 150 mg/mL and the methionine is at a concentration of 2.5 mM to about 134 mM.

32. The composition of claim 6 , wherein the secukinumab is at a concentration of about 150 mg/mL and the methionine is at a concentration of 2.5 mM to about 134 mM.

33. The composition of claim 14 , wherein the secukinumab is at a concentration of about 150 mg/mL and the methionine is at a concentration of 2.5 mM to about 134 mM.

34. The composition of claim 19 , wherein the secukinumab is at a concentration of about 150 mg/mL and the methionine is at a concentration of 2.5 mM to about 134 mM.

35. The composition of claim 24 , wherein the secukinumab is at a concentration of about 150 mg/mL and the methionine is at a concentration of 2.5 mM to about 134 mM.

36. The composition of claim 1 , wherein the methionine is at a concentration of 2.5 mM to about 134 mM.

37. The composition of claim 13, 18, or 23 , wherein the methionine is at a concentration of 2.5 mM to about 134 mM.

38. A pharmaceutical product comprising a container and the composition of claim 34 disposed within the container, wherein the product is a syringe or an autoinjector.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2026
From: NOVARTIS AG
To: NOVARTIS PHARMA AG
Reel/Frame 075712/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: JOERG, SUSANNE; SERNO-SCHERSCH, KATHRIN
To: NOVARTIS PHARMA AG
Reel/Frame 070254/0919 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 070255/0416 →
Continuity (4)
Continuation 18481213 · Oct 4, 2023
Division 15538257
Provisional Application 62095210 · Dec 22, 2014
Related Publication 20240415961A1 · Dec 19, 2024
References Cited (400)
US 5250442A · Cabezas · 1993 [cited by applicant]
US 5272135A · Harun et al. · 1993 [cited by applicant]
US 6309636B1 · do Couto et al. · 2001 [cited by applicant]
US 8119131B2 · Di Padova et al. · 2012 [cited by applicant]
US 8568720B2 · Morichika · 2013 [cited by applicant]
US 9717791B2 · Guettner et al. · 2017 [cited by applicant]
US 9744234B2 · Mpofu et al. · 2017 [cited by applicant]
US 11280479B2 · Meyer et al. · 2022 [cited by applicant]
US 20010055617A1 · Mattern · 2001 [cited by applicant]
US 20020052422A1 · Milstein · 2002 [cited by applicant]
US 20020081302A1 · Cvitkovitch · 2002 [cited by applicant]
US 20030012817A1 · Milstein · 2003 [cited by applicant]
US 20030104996A1 · Tiansheng et al. · 2003 [cited by applicant]
US 20040033228A1 · Krause · 2004 [cited by examiner]
US 20040038878A1 · Tanikawa et al. · 2004 [cited by applicant]
US 20050147609A1 · Filvaroff · 2005 [cited by applicant]
US 20070212362A1 · Filvaroff · 2007 [cited by applicant]
US 20080044423A1 · Cochrane et al. · 2008 [cited by applicant]
US 20080286280A1 · Kallmeyer · 2008 [cited by applicant]
US 20090136491A1 · Chen · 2009 [cited by applicant]
US 20100080812A1 · Auer · 2010 [cited by applicant]
US 20100092566A1 · Alessi · 2010 [cited by applicant]
US 20100266496A1 · Hansen · 2010 [cited by applicant]
US 20100266608A1 · Cooreman et al. · 2010 [cited by applicant]
US 20100272636A1 · Byrd · 2010 [cited by applicant]
US 20100285011A1 · Morichika · 2010 [cited by examiner]
US 20110263828A1 · Wong · 2011 [cited by applicant]
US 20120045848A1 · Haugland et al. · 2012 [cited by applicant]
US 20120100068A1 · Byrd · 2012 [cited by applicant]
US 20120183531A1 · Lucas et al. · 2012 [cited by applicant]
US 20130017191A1 · Werner et al. · 2013 [cited by applicant]
US 20130202610A1 · Guettner et al. · 2013 [cited by applicant]
US 20130209480A1 · Mpofu et al. · 2013 [cited by applicant]
US 20180008706A1 · Mpofu et al. · 2018 [cited by applicant]
CN 104011223A · 2014 [cited by applicant]
CN 104244979A · 2014 [cited by applicant]
EP 0734728A1 · 1996 [cited by applicant]
EP 0734729A1 · 1996 [cited by applicant]
EP 0734730A1 · 1996 [cited by applicant]
EP 2796429A1 · 2014 [cited by applicant]
EP 3111954A1 · 2017 [cited by applicant]
JP 2000186046A · 2000 [cited by applicant]
JP 2000186048A · 2000 [cited by applicant]
JP 2015519311A · 2015 [cited by applicant]
WO 8700196A1 · 1987 [cited by applicant]
WO 9423767A1 · 1994 [cited by applicant]
WO 9533488A1 · 1995 [cited by applicant]
WO 9632096A1 · 1996 [cited by applicant]
WO 9704801A1 · 1997 [cited by applicant]
WO 0045790A2 · 2000 [cited by applicant]
WO 0056772A1 · 2000 [cited by applicant]
WO 0069463A1 · 2000 [cited by applicant]
WO 0124814A1 · 2001 [cited by applicant]
WO 0185137A2 · 2001 [cited by applicant]
WO 0202642A2 · 2002 [cited by applicant]
WO 03020299A1 · 2003 [cited by applicant]
WO 03039467A2 · 2003 [cited by applicant]
WO 03039485A2 · 2003 [cited by applicant]
WO 03087335A2 · 2003 [cited by applicant]
WO 2004007520A2 · 2004 [cited by applicant]
WO 2004055164A2 · 2004 [cited by applicant]
WO 2004058156A2 · 2004 [cited by applicant]
WO 2004060343A1 · 2004 [cited by applicant]
WO 2004110498A2 · 2004 [cited by applicant]
WO 2005010044A2 · 2005 [cited by applicant]
WO 2005049078A2 · 2005 [cited by applicant]
WO 2005058365A1 · 2005 [cited by applicant]
WO 2005063291A1 · 2005 [cited by applicant]
WO 2005077414A1 · 2005 [cited by applicant]
WO 2006013107A1 · 2006 [cited by applicant]
WO 2006039704A2 · 2006 [cited by applicant]
WO 2006044908A2 · 2006 [cited by applicant]
WO 2006054059A1 · 2006 [cited by applicant]
WO 2006063864A2 · 2006 [cited by applicant]
WO 2006063865A2 · 2006 [cited by applicant]
WO 2006081587A2 · 2006 [cited by applicant]
WO 2006083689A2 · 2006 [cited by applicant]
WO 2006088833A2 · 2006 [cited by applicant]
WO 2006088925A2 · 2006 [cited by applicant]
WO 2006096011A1 · 2006 [cited by applicant]
WO 2006096488A2 · 2006 [cited by applicant]
WO 2006096491A2 · 2006 [cited by applicant]
WO 2006138181A2 · 2006 [cited by applicant]
WO 2007002543A2 · 2007 [cited by applicant]
WO 2007027761A2 · 2007 [cited by applicant]
WO 2007036745A2 · 2007 [cited by applicant]
WO 2007059188A1 · 2007 [cited by applicant]
WO 2007070750A1 · 2007 [cited by applicant]
WO 2007076062A2 · 2007 [cited by applicant]
WO 2007092829A2 · 2007 [cited by applicant]
WO 2007095288A2 · 2007 [cited by applicant]
WO 2007095337A2 · 2007 [cited by applicant]
WO 2007106769A2 · 2007 [cited by applicant]
WO 2007109221A2 · 2007 [cited by applicant]
WO 2007110339A1 · 2007 [cited by applicant]
WO 2007117749A2 · 2007 [cited by applicant]
WO 2007124299A2 · 2007 [cited by applicant]
WO 2007143701A2 · 2007 [cited by applicant]
WO 2007147019A2 · 2007 [cited by applicant]
WO 2007149032A1 · 2007 [cited by applicant]
WO 2007149814A1 · 2007 [cited by applicant]
WO 2008011571A1 · 2008 [cited by applicant]
WO 2008021156A2 · 2008 [cited by applicant]
WO 2008029908A1 · 2008 [cited by applicant]
WO 2008030611A2 · 2008 [cited by applicant]
WO 2008047134A2 · 2008 [cited by applicant]
WO 2008051363A2 · 2008 [cited by applicant]
WO 2008054603A2 · 2008 [cited by applicant]
WO 2008065304A1 · 2008 [cited by applicant]
WO 2008067223A2 · 2008 [cited by applicant]
WO 2008071394A1 · 2008 [cited by applicant]
WO 2008071751A1 · 2008 [cited by applicant]
WO 2008079359A2 · 2008 [cited by applicant]
WO 2008079890A1 · 2008 [cited by applicant]
WO 2008086395A2 · 2008 [cited by applicant]
WO 2008087329A2 · 2008 [cited by applicant]
WO 2008121615A2 · 2008 [cited by applicant]
WO 2008121865A1 · 2008 [cited by applicant]
WO 2008132439A2 · 2008 [cited by applicant]
WO 2008134659A2 · 2008 [cited by applicant]
WO 2008149143A2 · 2008 [cited by applicant]
WO 2008149144A2 · 2008 [cited by applicant]
WO 2008149146A2 · 2008 [cited by applicant]
WO 2008149147A2 · 2008 [cited by applicant]
WO 2008149148A2 · 2008 [cited by applicant]
WO 2008149149A2 · 2008 [cited by applicant]
WO 2008149150A2 · 2008 [cited by applicant]
WO 2008150479A2 · 2008 [cited by applicant]
WO 2008156865A2 · 2008 [cited by applicant]
WO 2009003096A2 · 2008 [cited by applicant]
WO 2009006301A2 · 2009 [cited by applicant]
WO 2009007272A1 · 2009 [cited by applicant]
WO 2009015063A2 · 2009 [cited by applicant]
WO 2009025763A2 · 2009 [cited by applicant]
WO 2009037190A2 · 2009 [cited by applicant]
WO 2009055343A2 · 2009 [cited by applicant]
WO 2009064838A1 · 2009 [cited by applicant]
WO 2009074634A2 · 2009 [cited by applicant]
WO 2009080541A1 · 2009 [cited by applicant]
WO 2009084659A1 · 2009 [cited by applicant]
WO 2009089036A2 · 2009 [cited by applicant]
WO 2009100297A1 · 2009 [cited by applicant]
WO 2009130459A2 · 2009 [cited by applicant]
WO 2009133103A1 · 2009 [cited by applicant]
WO 2009141239A1 · 2009 [cited by applicant]
WO 2009149168A2 · 2009 [cited by applicant]
WO 2009149189A2 · 2009 [cited by applicant]
WO 2010006060A2 · 2010 [cited by applicant]
WO 2010017296A1 · 2010 [cited by applicant]
WO 2010025400A2 · 2010 [cited by applicant]
WO 2010030670A2 · 2010 [cited by applicant]
WO 2010032220A1 · 2010 [cited by applicant]
WO 2009136286A9 · 2010 [cited by applicant]
WO 2010034443A1 · 2010 [cited by applicant]
WO 2010042705A1 · 2010 [cited by applicant]
WO 2010056804A1 · 2010 [cited by applicant]
WO 2010060768A1 · 2010 [cited by applicant]
WO 2010062858A1 · 2010 [cited by applicant]
WO 2010062896A1 · 2010 [cited by applicant]
WO 2010065491A2 · 2010 [cited by applicant]
WO 2010066762A1 · 2010 [cited by applicant]
WO 2010069858A1 · 2010 [cited by applicant]
WO 2010081091A2 · 2010 [cited by applicant]
WO 2010091637A1 · 2010 [cited by applicant]
WO 2010100179A2 · 2010 [cited by applicant]
WO 2010102241A1 · 2010 [cited by applicant]
WO 2010102251A2 · 2010 [cited by applicant]
WO 2010114859A1 · 2010 [cited by applicant]
WO 2010123798A2 · 2010 [cited by applicant]
WO 2010124009A2 · 2010 [cited by applicant]
WO 2010128407A2 · 2010 [cited by applicant]
WO 2010148337A1 · 2010 [cited by applicant]
WO 2011005354A2 · 2011 [cited by applicant]
WO 2011008770A2 · 2011 [cited by applicant]
WO 2011012637A2 · 2011 [cited by applicant]
WO 2011023685A1 · 2011 [cited by applicant]
WO 2011028961A2 · 2011 [cited by applicant]
WO 2011028962A1 · 2011 [cited by applicant]
WO 2011029892A2 · 2011 [cited by applicant]
WO 2011034604A2 · 2011 [cited by applicant]
WO 2011044563A2 · 2011 [cited by applicant]
WO 2011053763A2 · 2011 [cited by applicant]
WO 2011076702A1 · 2011 [cited by applicant]
WO 2011080209A2 · 2011 [cited by applicant]
WO 2011096438A1 · 2011 [cited by applicant]
WO 2011104315A2 · 2011 [cited by applicant]
WO 2011112669A1 · 2011 [cited by applicant]
WO 2011139718A1 · 2011 [cited by applicant]
WO 2011141823A2 · 2011 [cited by applicant]
WO 2011161226A2 · 2011 [cited by applicant]
WO 2011163452A2 · 2011 [cited by applicant]
WO 2012018767A2 · 2012 [cited by applicant]
WO 2012028683A1 · 2012 [cited by applicant]
WO 2012045848A1 · 2012 [cited by applicant]
WO 2012064627A2 · 2012 [cited by applicant]
WO WO2012059598A2 · 2012 [cited by examiner]
WO 2012082573A1 · 2012 [cited by applicant]
WO 2012094623A2 · 2012 [cited by applicant]
WO 2012095662A1 · 2012 [cited by applicant]
WO 2011088120A9 · 2012 [cited by applicant]
WO 2012103345A1 · 2012 [cited by applicant]
WO 2012121754A1 · 2012 [cited by applicant]
WO 2012151199A1 · 2012 [cited by applicant]
WO 2012154999A1 · 2012 [cited by applicant]
WO 2013057241A1 · 2013 [cited by applicant]
WO 2013063510A1 · 2013 [cited by applicant]
WO 2013077907A1 · 2013 [cited by applicant]
WO 2013083497A1 · 2013 [cited by applicant]
WO 2013087911A1 · 2013 [cited by applicant]
WO 2013087912A1 · 2013 [cited by applicant]
WO 2013087913A1 · 2013 [cited by applicant]
WO 2013087914A1 · 2013 [cited by applicant]
WO 2012156219A9 · 2013 [cited by applicant]
WO 2013134052A1 · 2013 [cited by applicant]
WO 2013158821A2 · 2013 [cited by applicant]
WO 2013164789A2 · 2013 [cited by applicant]
WO 2013164837A1 · 2013 [cited by applicant]
WO 2013186236A1 · 2013 [cited by applicant]
WO 2014001368A1 · 2014 [cited by applicant]
WO 2014036071A1 · 2014 [cited by applicant]
WO 2014036076A1 · 2014 [cited by applicant]
WO 2014044758A1 · 2014 [cited by applicant]
WO 2014076321A1 · 2014 [cited by applicant]
WO 2014085305A1 · 2014 [cited by applicant]
WO 2014090888A1 · 2014 [cited by applicant]
WO 2014096672A1 · 2014 [cited by applicant]
WO 2014122613A1 · 2014 [cited by applicant]
WO 2014141152A2 · 2014 [cited by applicant]
WO 2014143909A1 · 2014 [cited by applicant]
WO 2014146575A1 · 2014 [cited by applicant]
WO 2014096051A9 · 2014 [cited by applicant]
WO 2014155278A2 · 2014 [cited by applicant]
WO 2014160883A1 · 2014 [cited by applicant]
WO 2014161570A1 · 2014 [cited by applicant]
WO 2014186665A2 · 2014 [cited by applicant]
WO 2015049519A2 · 2015 [cited by applicant]
WO 2014114651A9 · 2016 [cited by applicant]
WO 2016103153A1 · 2016 [cited by applicant]
WO 2017068472A1 · 2017 [cited by applicant]
ACR Call for Late-Breaking Abstracts, Guidelines for Submission, Nov. 10-14, 2022. [cited by applicant]
ACR/ARHP Call for abstracts Guidelines, Oct. 2010. [cited by applicant]
Aletaha, et al., 2010 Rheumatoid arthritis classifi cation criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Annals of Rheumatic Diseases, 69, 1580-1588, 2010. [cited by applicant]
Amgen Wyeth Press Release, Jul. 24, 2003, ENBREL Is First Biologic to Receive FDA Approval for the Treatment of Ankylosing Spondylitis. [cited by applicant]
Anonymous: ““Object”—Definition & Meaning—Merriam-Webster”, , Dec. 8, 2021 (Dec. 8, 2021), pp. 1-15, XP055870736, Retrieved from the Internet: URL:https://www.merriam-webster.com/dictionary/object [retrieved on Dec. 8, … [cited by applicant]
Baeten, et al., Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, 382(9906), 1705-1713, Nov. 23, 2013. [cited by applicant]
Baeten, et al., Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with In… [cited by applicant]
Baeten, et al., Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med, 373(26), 2534-2548, Dec. 24, 2015. [cited by applicant]
Baeten, et al., The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) Showed Good Safety and Efficacy in the Treatment of Active Ankylosing Spondylitis, Annals of Rheumatic Diseases, 70(3), 127, 2011. [cited by applicant]
Baeten, et al., The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) Showed Good Safety and Efficacy in the Treatment of Active Ankylosing Spondylitis, Arthritis and Rheumatism, 62(12), 3840-3841, 2010. [cited by applicant]
Baeten, et al., The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) Showed Good Safety and Efficacy in the Treatment of Active Ankylosing Spondylitis, Late Breaking Abstracts: American College of Rheumatology 2010 A… [cited by applicant]
Balague, et al., Understanding autoimmune disease: new targets for drug discovery, Drug Discovery Today, 14(19-20), 926-934, Oct. 2009. [cited by applicant]
Baraliakos, et al., 2486D—Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis as Early as Week 6, As Detected by Magnetic Resonance Imaging, ACR/ARHP Scientific … [cited by applicant]
Baraliakos, et al., Biologic Therapies for Spondyloartritis: What is new?, Current Rheumatology Reports, 14, 422-427, Aug. 2, 2012. [cited by applicant]
Baraliakos, et al., Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study, Annals of Rheumatic Diseases, 75, 408-412, Au… [cited by applicant]
Baron-Faust, The IL-17 Superfamily: What Future for PsA?, Rheumatology Network, Mar. 18, 2014. [cited by applicant]
Baseggio, et al., ContainerClosureIntegrityofaGlassPrefillableSyringeinDeepFrozenStorageConditions, Journal of Pharmaceutical Sciences, 113, 1248-1256, 2024. [cited by applicant]
Bee, et al., Formulation strategy and tactics for mAbs: not all mAbs are the same, Monoclonal Antibodies: Development, Delivery and Applications, 43-57, 2015. [cited by applicant]
Benhamou, et al., Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein, Rheumatology, 49(3), 536-541, 2010. [cited by applicant]
Bhambhani, et al., Lyophilization Strategies for Development of a HighConcentration Monoclonal Antibody Formulation: Benefits and Pitfalls, American Pharmaceutical Review, Jan. 1, 2010. [cited by applicant]
Boehncke, et al., Burden of Disease: Psoriasis and Psoriatic Arthritis, American Journal of Clinical Dermatology, 14, 377-388, 2013. [cited by applicant]
Bontempo, Parenteral Formulation for Peptides, Proteins, and Monoclonal Antibodies Drugs: A Commercial Development Overview, Drug Delivery: Principles and Applications, 321-339, 2005. [cited by applicant]
Boswell, et al., Effects of charge on antibody tissue distribution and pharmacokinetics, Bioconjugate Chemistry, 21, 2153-2163, 2010. [cited by applicant]
Braun, et al., 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Annals of Rheumatic Diseases, 70, 896-904, 2011. [cited by applicant]
Braun, et al., Emerging drugs for the treatment of axial and peripheral spondyloarthritis, Expert Opinion on Emerging Drugs, 20(1), 1-14, Jan. 9, 2015. [cited by applicant]
Braun, et al., Secukinumab (AIN457) in the treatment of ankylosing spondylitis, Expert Opinion on Biological Therapy, 16(5), 711-722, Apr. 7, 2016. [cited by applicant]
Buggage, et al., The Study of IL-17A Expression as a Biomarker for Patients With Active Noninfectious Uveitis Treated With AIN457, Presentation Abstract, May 4, 2010. [cited by applicant]
Bye, et al., Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments, Biotechnology Letters, Feb. 21, 2014. [cited by applicant]
Carpenter, et al., Rational Design of Stable Protein Formulations, 2002. [cited by applicant]
Caudill, et al., Container Closure Integrity Test Using Frequency Modulation Spectroscopy Headspace Analysis with Carbon Dioxide as a Tracer Gas, PDA J Pharm Sci and Tech, 75(2), 157-172, Mar.-Apr. 2021. [cited by applicant]
Chandran, et al., Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort, Journal of Rheumatology, 35(3), 469-471, 2008. [cited by applicant]
Chang, et al., Mechanisms of Protein Stabilization in the Solid State, Journal of Pharmaceutical Sciences, 98(9), 2886-2908, Sep. 2009. [cited by applicant]
Chang, et al., Practical Approaches to Protein Formulation Development, Rationale Design of Stable Protein Formulations—Theory and Practice, 1-25, 2002, Kluwer Academic, New York. [cited by applicant]
Chen, et al., Sulfasalazine for ankylosing spondylitis (Review), The Cochrane Collaboration, 2005. [cited by applicant]
Chioato, et al., Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects Exposed to Secukinumab 150 Mg: Preliminary Study Results., Arthritis and Rheumatism, 63(10), S711, Oct. 2011. [cited by applicant]
Chu, et al., A Comprehensive Picture of Non-Site Specific Oxidation of Methionine Residues by Peroxides in Protein Pharmaceuticals, Journal of Pharmaceutical Sciences, 93(12), 3096-3102, Dec. 2004. [cited by applicant]
Chu, et al., A Structural and Mechanistic Study of the Oxidation of Methionine Residues in hPTH(1-34) via Experiments and Simulations, Biochemistry, 43, 14139-14148, 2004. [cited by applicant]
Chu, et al., Molecular Dynamics Simulations and Oxidation Rates of Methionine Residues of Granulocyte Colony-Stimulating Factor at Different pH Values, Biochemistry, 43(4), 1019-1029, 2004. [cited by applicant]
Chu, et al., On the Mechanisms of Oxidation of Organic Sulfides by H2O2 in Aqueous Solutions, JACS, 126, 900-908, 2004. [cited by applicant]
Chu, et al., Oxidation of Methionine Residues in Aqueous Solutions: Free Methionine and Methionine in Granulocyte Colony-Stimulating Factor, JACS, 126, 16601-16607, 2004. [cited by applicant]
Ciccia, et al., Overexpression of Interleukin-23, but Not Interleukin-17, as an Immunologic Signature of Subclinical Intestinal Inflammation in Ankylosing Spondylitis, Arthritis and Rheumatism, 60(4), 955-965, Apr. 2009. [cited by applicant]
Cimzia prescribing information, revised Jul. 2010, 25 pages. [cited by applicant]
Clinical trial NCT00809159, Dec. 16, 2008, available at https://www.clinicaltrials.gov/ct2/show/NCT00809159. [cited by applicant]
Clinical trial NCT00809159, Jun. 22, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT00809159. [cited by applicant]
Clinical trial NCT00809614, Apr. 29, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT00809614. [cited by applicant]
Clinical Trial NCT00928512, Jul. 29, 2015, available at https://clinicaltrials.gov/ct2/show/NCT00928512. [cited by applicant]
Clinical Trial NCT00928512, Jun. 25, 2009, available at https://clinicaltrials.gov/ct2/show/NCT00928512. [cited by applicant]
Clinical trial NCT01107457, Apr. 21, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01107457. [cited by applicant]
Clinical trial NCT01109940, Jun. 22, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01109940. [cited by applicant]
Clinical trial NCT01169844, Jul. 23, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01169844. [cited by applicant]
Clinical trial NCT01649375, Jul. 25, 2012, available at https://www.clinicaltrials.gov/ct2/show/NCT01649375. [cited by applicant]
Clinical trial NCT01870284, last updated Sep. 15, 2014, available at https://www.clinicaltrials.gov/ct2/show/NCT01870284. [cited by applicant]
Clinical trial NCT02696785, Feb. 26, 2016, available at https://www.clinicaltrials.gov/ct2/show/NCT02696785. [cited by applicant]
Clinical Trial NCT04209205, Dec. 24, 2019, available at https://www.clinicaltrials.gov/ct2/show/NCT04209205. [cited by applicant]
Cosentyx prescribing information, revised Aug. 17, 2017, 44 pages. [cited by applicant]
Cosentyx prescribing information, revised Jan. 2016, 32 pages. [cited by applicant]
Cosentyx prescribing information, revised Jan. 2020. [cited by applicant]
Cosentyx Summary of Products Characteristics, Sep. 1, 2017. [cited by applicant]
Cross, et al., Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999, Pharmacoepidemiology and Drug Safety, 11, 439-446, Aug. 12, 2002. [cited by applicant]
Cui, et al., Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system, Drug Development and Industrial Pharmacy, 43(4), 519-530, Jan. 22, 2017. [cited by applicant]
Cui, et al., Pharmaceutics, 2nd edition, 24 pages, 2011. [cited by applicant]
Curriculum Vitae Brian Oscar Porter, Feb. 2017. [cited by applicant]
Curriculum Vitae Didier Renard, Feb. 2017. [cited by applicant]
Daikh, et al., Advances in managing ankylosing spondylitis, F1000 Prime Reports, 6(78), Sep. 4, 2014. [cited by applicant]
Danve, et al., IL-17 Inhibition in Axial Spondyloarthritis, Current Treatment Options in Rheumatology, 1, 221-230, Apr. 2, 2015. [cited by applicant]
Das, Commercializing High-Concentration mAbs, BioPharm International, 29(11), 47-49, 2016. [cited by applicant]
Daugherty, et al., Formulation and delivery issues for monoclonal antibody therapeutics, Advanced Drug Delivery Reviews, 58, 686-706, May 22, 2006. [cited by applicant]
Davis, et al., Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis, Arthritis and Rheumatism, 48(11), 3230-3236, Nov. 2003. [cited by applicant]
Declaration of Dr. Brian Oscar Porter, dated Feb. 21, 2017. [cited by applicant]
Declaration of Dr. Diane R. Mould, dated Jan. 29, 2014. [cited by applicant]
Declaration of Dr. Oliver Sander, dated Oct. 19, 2015. [cited by applicant]
Declaration of Dr. Renard Didier, dated Mar. 2, 2017. [cited by applicant]
Deodhar, et al., Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: Result from a phase 3 double-blind, randomized, placebo-controlled study, ACR/ARP Annual Meeting… [cited by applicant]
Deodhar, et al., Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: Result from a phase 3 double-blind, randomized, placebo-controlled study, ACR/ARP annual meeting… [cited by applicant]
Deodhar, et al., Secukinumab significantly improves physical function, quality of life, and work productivity through 52 weeks in subjects with active ankylosing spondylitis in the phase 3 measure 2 study, Annals of Rhe… [cited by applicant]
Deodhar, et al., The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis, Annals of Rheumatic Diseases, 75, 791-794, 2016. [cited by applicant]
Dick, et al., Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials, Ophthalmology, 120(4), 777-787, Apr. 2013. [cited by applicant]
Dougados, et al., Arthritis 2 Spondyloarthritis, Lancet, 377, 2127-2137, 2011. [cited by applicant]
Duncan, et al., The Application of Noninvasive Headspace Analysis to Media Fill Inspection, PDA Journal of Pharmaceutical Science and Technology, 70(3), 230-247, May-Jun. 2016. [cited by applicant]
EMA, “Summary of Opinion Cosentyx”, dated Nov. 20, 2014, available at http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003729/WC500177620.pdf. [cited by applicant]
EMA, Committee for Medicinal Products for Human Use (CHMP), Cosentyx assessment report, Nov. 20, 2014. [cited by applicant]
EMA, Guide to information on human medicines, EMA/515416/2015, 2017, available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500183131&mid=WC0b01ac058009a3dc. [cited by applicant]
EPO, Communication pursuant to Article 94(3) EPC, for counterpart EP 15823805.0 dated May 9, 2018. [cited by applicant]
European public assessment report page screenshot, dated Aug. 29, 2018, available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500183131&mid=WC0b01ac058009a3d… [cited by applicant]
Fagerli, et al., Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study, Annals of Rheumatic Diseases, 72, 1840-1844, Apr. 5, 2013. [cited by applicant]
Falconer, Advances in Liquid Formulations of Parenteral Therapeutic Proteins, Biotechnology Advances, 37, Jun. 27, 2019. [cited by applicant]
Freeman, Secukinumab improves patient-reported outcomes in ankylosing spondylitis, MDedge, Apr. 27, 2016. [cited by applicant]
Frokjaer, et al., Protein Drug Stability: A Formulation Challenge, Nature Reviews: Drug Discovery, 4, 298-306, Apr. 2005. [cited by applicant]
Gaffen, et al., The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing, Nature Reviews Immunology, 14, 585-600, Sep. 2014. [cited by applicant]
Genco, FDA Approval of the First nr-AxSpA Biologics: Projecting Regulatory & Market Dynamics, Biosimilar Development, Feb. 27, 2019. [cited by applicant]
Genovese, et al., Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study, Annals of Rheumatic Diseases, 72, 863-869, 2013. [cited by applicant]
Genovese, et al., LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis, Arthritis and Rheumatism, 62(4), 929-939, Apr. 2010. [cited by applicant]
Genovese, et al., Secukinumab (AIN457) showed a rapid decrease of disease activity in patients with active rheumatoid arthritis including those with high inflammatory burden, Annals of Rheumatic Diseases, 70(3), 472, 20… [cited by applicant]
Genovese, et al., Secukinumab (AIN457), a Novel Monoclonal Antibody Targeting IL-17A Demonstrates Efficacy in Active Rheumatoid Arthritis Patients Despite Stable Methotrexate Treatment: Results of a Phase llb Study, Art… [cited by applicant]
Gladman, et al., Psoriatic arthritis: epidemiology, clinical features, course, and outcome, Annals of Rheumatic Diseases, 64(II), ii14-ii17, 2005. [cited by applicant]
Goh, et al., Update on biologic therapies in ankylosing spondylitis: a literature review, International Journal of Rheumatic Disease, 15, 445-454, 2012. [cited by applicant]
Goodman, Secukinumab Successful in Spondylitis, Psoriatic Arthritis, Medscape, Nov. 24, 2014. [cited by applicant]
Gossec, et al., European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Annals of Rheumatic Diseases, 71, 4-12, 2012. [cited by applicant]
Goswami, et al., Developments and Challenges for mAb-Based Therapeutics, Antibodies, 2, 452-500, Aug. 16, 2013. [cited by applicant]
Gottlieb, et al., Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics, Journal of th… [cited by applicant]
Gottlieb, et al., Secukinumab Reduces Hscrp Levels in Subjects with Moderate-To-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Sub-Analysis from the Phase 3 Erasure Study, Annals of the Rheumatic Disease… [cited by applicant]
Gottlieb, et al., Secukinumab Shows Substantial Improvement in Both Psoriasis Symptoms and Physical Functioning in Moderateto-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis of a Phase 3, Multic… [cited by applicant]
Goulabchand, et al., Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials, Annals of Rheumatic Diseases, 73,… [cited by applicant]
Griffiths, et al., Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines, Clin Exp Rheumatol, 24(40), S72-S78, 2006. [cited by applicant]
Haibel, et al., Open label trial of anakinra in active ankylosing spondylitis over 24 weeks, Annals of Rheumatic Diseases, 64, 296-298, 2005. [cited by applicant]
Haller, Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase, Pharmaceutical Technology, Oct. 2, 2007. [cited by applicant]
Hennigan, et al., Adalimumab in ankylosing spondylitis: an evidence_based review of its place in therapy, Core Evidence, 2(4), 295-305, 2008. [cited by applicant]
Herceptin® [Trastuxumab], FDA Label, Sep. 1998. [cited by applicant]
History of changes for Study NCT00669916, submitted on Apr. 9, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00669916?V_5=View. [cited by applicant]
History of changes for Study NCT00669942, submitted on Mar. 27, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00669942?A=5&B=5&C=merged. [cited by applicant]
History of changes for Study NCT00805480, submitted on Jan. 28, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00805480?V_4=View. [cited by applicant]
History of changes for Study NCT00809159, submitted on Dec. 7, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00809159?V_9=View#StudyPageTop. [cited by applicant]
History of changes for Study NCT00809614, submitted on Oct. 14, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00809614?A=5&B=5&C=merged. [cited by applicant]
History of Changes for Study NCT00928512, Mar. 12, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT00928512. [cited by applicant]
History of changes for Study NCT00928512, submitted on Oct. 7, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00928512?V_9=View#StudyPageTop. [cited by applicant]
History of Changes for Study NCT00995709, Oct. 14, 2009, available at https://www.clinicaltrials.gov/ct2/show/NCT00995709. [cited by applicant]
History of changes for Study NCT00995709, submitted on Aug. 13, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00995709?V_7=View. [cited by applicant]
History of Changes for Study NCT01032915, Oct. 24, 2010, available at https://www.clinicaltrials.gov/study/NCT01032915. [cited by applicant]
History of changes for Study NCT01032915, submitted on Oct. 8, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01032915?V_4=View. [cited by applicant]
History of Changes for Study NCT01071252, Feb. 18, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01071252. [cited by applicant]
History of changes for Study NCT01071252, submitted on Feb. 12, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01071252?V_1=View. [cited by applicant]
History of Changes for Study NCT01090310, Sep. 28, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01090310. [cited by applicant]
History of changes for Study NCT01090310, submitted on Dec. 8, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01090310?V_2=View. [cited by applicant]
History of changes for Study NCT01093846 submitted on Jan. 22, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01093846?V_2=View. [cited by applicant]
History of Changes for Study NCT01093846, Oct. 13, 2010, available at https://www.clinicaltrials.gov/study/NCT01093846. [cited by applicant]
History of Changes for Study NCT01095250, Oct. 13, 2010, available at https://clinicaltrials.gov/ct2/history/NCT01095250?A=6&B=6&C=merged. [cited by applicant]
History of changes for Study NCT01095250, submitted on Oct. 5, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01095250?A=6&B=6&C=merged. [cited by applicant]
History of Changes for Study NCT01103024, Oct. 15, 2010, available at https://clinicaltrials.gov/study/NCT01103024?a=2&tab=history. [cited by applicant]
History of changes for Study NCT01103024, submitted on May 2, 2012, available at https://clinicaltrials.gov/ct2/history/NCT01103024?A=2&B=2&C=merged. [cited by applicant]
History of changes for Study NCT01109940, submitted on Nov. 15, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01109940?V_2=View. [cited by applicant]
History of changes for Study NCT01169844, submitted on Nov. 16, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01169844?A=1&B=1&C=merged. [cited by applicant]
History of Changes for Study NCT01327664, Mar. 31, 2011, available at https://clinicaltrials.gov/study/NCT01327664?tab=history&a=1. [cited by applicant]
History of changes for Study NCT01327664, submitted on Dec. 5, 2013, available at https://clinicaltrials.gov/ct2/history/NCT01327664?V_1=View. [cited by applicant]
History of Changes for Study NCT01350804, Sep. 23, 2011, available at https://clinicaltrials.gov/study/NCT01350804?tab=history&a=3. [cited by applicant]
History of changes for Study NCT01350804, submitted on May 4, 2016, available at https://clinicaltrials.gov/ct2/history/NCT1350804?A=3&B=3&C=merged. [cited by applicant]
History of changes for Study NCT01358175, submitted on Oct. 20, 2011, available at https://clinicaltrials.gov/ct2/history/NCT01358175?V_2=View#StudyPageTop. [cited by applicant]
History of Changes for Study NCT01358578, Aug. 17, 2011, available at https://clinicaltrials.gov/study/NCT01358578?tab=history&a=6. [cited by applicant]
History of changes for Study NCT01358578, submitted on Mar. 29, 2019, available at https://clinicaltrials.gov/ct2/history/NCT01358578?A=6&B=6&C=merged. [cited by applicant]
History of Changes for Study NCT01365455, Oct. 12, 2011, available at https://clinicaltrials.gov/study/NCT01365455?a=10&tab=history. [cited by applicant]
History of changes for Study NCT01365455, submitted on Mar. 20, 2019, available at https://clinicaltrials.gov/ct2/history/NCT01365455?A=10&B=10&C=merged. [cited by applicant]
History of Changes for Study NCT01377012, Sep. 28, 2011, available at https://clinicaltrials.gov/study/NCT01377012?a=4&tab=history. [cited by applicant]
History of changes for Study NCT01377012, submitted on Feb. 9, 2017, available at https://clinicaltrials.gov/ct2/history/NCT1377012?A=4&B=4&C=merged. [cited by applicant]
History of Changes for Study NCT01392326, Sep. 23, 2011, available at https://clinicaltrials.gov/study/NCT01392326?tab=history&a=2. [cited by applicant]
History of changes for Study NCT01392326, submitted on Jan. 5, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01392326?A=2&B=2&C=merged. [cited by applicant]
History of Changes for Study NCT01406938, Aug. 15, 2011, available at https://clinicaltrials.gov/study/NCT01406938?a=2&tab=history. [cited by applicant]
History of changes for Study NCT01406938, submitted on Apr. 30, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01406938?A=2&B=2&C=merged. [cited by applicant]
History of Changes for Study NCT01412944, Aug. 8, 2011, available at https://clinicaltrials.gov/study/NCT01412944?tab=history&a=1. [cited by applicant]
History of changes for Study NCT01412944, submitted on Mar. 17, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01412944?A=1&B=1&C=merged. [cited by applicant]
History of changes for Study NTC01359943, submitted on Oct. 18, 2011, available at https://clinicaltrials.gov/ct2/history/NCT01359943?V_2=View. [cited by applicant]
Hou, et al., Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-alpha and IL-17A expressions, Journal of Zhejiang University—Science B, 12(1), 40-46, 2011. [cited by applicant]
Hueber, et al., Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis, Science Translational Medicine, 2(52), 52ra72, Oct. 6, 2010. [cited by applicant]
Hueber, et al., Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial, Gut, 61, 1693-1700, 2012. [cited by applicant]
Humira prescribing information, revised Mar. 2020. [cited by applicant]
Igawa, et al., Reduced elimination of IgG antibodies by engineering the variable region, Protein Engineering, Design and Selection, 23(5), 385-392, Feb. 15, 2010. [cited by applicant]
Inman, et al., Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis, Arthritis and Rheumatism, 58(11), 3402-3412, Nov. 2008. [cited by applicant]
International Nonproprietary Names for Pharmaceutical Substances (INN), WHO Drug Information, 24(3), 259-290, 2010. [cited by applicant]
Jacob, et al., Stability of Proteins in Aqueous Solution and Solid State, Indian Journal of Pharmaceutical Sciences, 68(2), 154-163, Apr. 9, 2006. [cited by applicant]
Jandus, et al., Increased Nos. of Circulating Polyfunctional Th17 Memory Cells in Patients With Seronegative Spondylarthritedes, Arthritis and Rheumatism, 58(8), 2307-2317, Aug. 2008. [cited by applicant]
Kagan, et al., Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats, Pharmaceutical Research, 29, 490-499, 2012. [cited by applicant]
Kang, et al., Rapid Formulation Development for Monoclonal Antibodies, BioProcess International, 14(4), 40-45, Apr. 2016. [cited by applicant]
Katdare, et al., Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems, 12 pages, 2006. [cited by applicant]
Cited By (1)
US 12,570,737